Clinical Trials Logo

Bacterial Conjunctivitis clinical trials

View clinical trials related to Bacterial Conjunctivitis.

Filter by:

NCT ID: NCT00565123 Completed - Clinical trials for Bacterial Conjunctivitis

Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjunctivitis

Start date: September 2004
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of the study is to evaluate the clinical and microbiological efficacies of three times daily administration of levofloxacin 0,5% eye drops as compared to the more frequent dosing (up to 8 times a day during the first 2 days and up to 4 times a day during the next 3 days) in patients with bacterial conjunctivitis.

NCT ID: NCT00518089 Completed - Clinical trials for Bacterial Conjunctivitis

A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis

Start date: February 2008
Phase: Phase 3
Study type: Interventional

The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis

NCT ID: NCT00509873 Completed - Clinical trials for Bacterial Conjunctivitis

A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis

Start date: August 2007
Phase: Phase 3
Study type: Interventional

The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis

NCT ID: NCT00464438 Completed - Clinical trials for Bacterial Conjunctivitis

A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis

Start date: June 2007
Phase: Phase 4
Study type: Interventional

This is a 7 day study to evaluate the safety and efficacy of topical gatifloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in subjects from birth to 31 days of age

NCT ID: NCT00332293 Completed - Clinical trials for Bacterial Conjunctivitis

AL-15469A for the Treatment of Bacterial Conjunctivitis

Start date: May 2006
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.

NCT ID: NCT00331916 Completed - Clinical trials for Bacterial Conjunctivitis

AL-15469A for the Treatment of Bacterial Conjunctivitis

Start date: November 2005
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.

NCT ID: NCT00312338 Completed - Clinical trials for Bacterial Conjunctivitis

Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora

Start date: June 2006
Phase: Phase 4
Study type: Interventional

Topical Treatment of Bacterial Conjunctivitis and its Effect on Microbial Flora

NCT ID: NCT00105534 Completed - Clinical trials for Bacterial Conjunctivitis

Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)

Start date: July 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the clinical and microbial efficacy and safety of AzaSite compared to vehicle for bacterial conjunctivitis. Adults and children one year of age and older with bacterial conjunctivitis in at least one eye may be eligible. Subjects will be randomly assigned to receive either 1.0 % AzaSite or Vehicle. Three visits will be required for this study.

NCT ID: NCT00105469 Completed - Clinical trials for Bacterial Conjunctivitis

Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)

Start date: July 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the clinical and microbial efficacy and safety of AzaSite compared to tobramycin for bacterial conjunctivitis. Adults and children one year of age and older with bacterial conjunctivitis in at least one eye are eligible. Subjects will be randomly assigned to the AzaSite group or Tobramycin group. Three visits will be required for the study.